EMA Seeks Clarity On Generics Of Drugs Approved Under Exceptional Circumstances
Executive Summary
The European Medicines Agency has asked the European Commission to clarify whether generics of drugs authorized under exceptional circumstances should be subject to the same obligations as the reference product.
You may also be interested in...
New Standard Of Care Secures EU OK For Neuroblastoma Drug
Changes in the EU in the standard of care for high-risk neuroblastoma has resulted in EUSA Pharma’s monoclonal antibody being approved by the European Commission under exceptional circumstances.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.